[This story originally ran April 1, 2019.]
Nephron Pharmaceuticalshas announced a new serialization initiative in which Kit Check Radio-Frequency Identification (RFID) tags are embedded on all prefilled syringe products at its Nephron 503B Outsourcing Facility.
The goal is to ensure all products are identifiable throughout the supply chain, using tracking and automation tools. Each pre-tagged syringe will work automatically in a Kit Check scanning station; no additional labeling or activation necessary.
The serialization effort will provide enhanced data on drug usage, allowing Nephron to tailor products to specifically suit the needs of a hospital. Products including Phenylephrine, Succinylcholine, Glycopyrrolate and more are available.
“Nephron is proud to be the first company implementing Kit Check across all syringe products,” says Lou Kennedy, Chief Executive Officer, Nephron. “We believe this will set a standard of care within our industry.”
“Kit Check is happy to support this effort with an automated solution for adding serialized RFID tags to prefilled syringes,” says Nick Petersen, Vice President at Kit Check. “We have tracked more than 50 million medications in the U.S. and learned the best approach for syringes is embedding the item-level tags at the time of production. More than 400 hospitals using Kit Check can now automatically recognize Nephron 503B prefilled syringes out-of-the-box.”
Nephron is one of nine partners certified for the Works with Kit Check program. Customers will no longer be required to add RFID tags to prefilled syringes to use them with Kit Check. Scanners will automatically identify the syringes in terms of NDC, lot number, and expiration date, saving time for hospital staff and reducing the risk of medical error.